<p>資金雄厚的投資者對諾和諾德公司（Novo Nordisk NVO）採取了看漲的態度，這一點市場參與者不應忽視。我們在 Benzinga 跟蹤公共期權記錄時，今天揭示了這一重大舉動。這些投資者的身份仍然未知，但 NVO 的如此大規模動作通常暗示着一些重大事件即將發生。</p>
<p>我們今天的觀察中得知這一信息，當 Benzinga 的期權掃描儀突出了諾和諾德的 17 個異常期權活動時。這種活動水平非常不尋常。</p>
<p>這些重量級投資者的整體情緒分歧，52% 傾向於看漲，35% 看跌。在這些顯著的期權中，有 9 個是看跌期權，總計 352,686 美元，8 個是看漲期權，總計 577,375 美元。</p>
<h3>價格目標是什麼？</h3>
<p>分析這些合約的成交量和未平倉合約，似乎大玩家在過去一個季度內關注諾和諾德的價格區間為 75.0 美元到 155.0 美元。</p>
<h3>成交量與未平倉合約趨勢</h3>
<p>查看成交量和未平倉合約是對股票進行盡職調查的一個有益方式。</p>
<p>這些數據可以幫助你跟蹤諾和諾德在特定行權價的期權流動性和興趣。</p>
<p>下面，我們可以觀察到諾和諾德在過去 30 天內所有鯨魚活動的看漲和看跌期權的成交量和未平倉合約的演變，行權價範圍為 75.0 美元到 155.0 美元。</p>
<h3>諾和諾德過去 30 天的期權成交量和未平倉合約</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2024/1734115610_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2024/1734115610_0.png"/></p>
<h3>值得注意的期權活動：</h3>
<table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行權價</strong></th>
<th><strong>總交易價格</strong></th>
<th><strong>未平倉合約</strong></th>
<th><strong>成交量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>12/20/24</td>
<td>$3.35</td>
<td>$3.15</td>
<td>$3.7</td>
<td>$109.00</td>
<td>$185.0K</td>
<td>1.0K</td>
<td>554</td>
</tr>
<tr>
<td>NVO</td>
<td>看漲</td>
<td>掃描</td>
<td>看漲</td>
<td>01/17/25</td>
<td>$5.0</td>
<td>$4.8</td>
<td>$5.0</td>
<td>$110.00</td>
<td>$96.5K</td>
<td>3.9K</td>
<td>253</td>
</tr>
<tr>
<td>NVO</td>
<td>看漲</td>
<td>交易</td>
<td>中性</td>
<td>01/17/25</td>
<td>$19.0</td>
<td>$17.9</td>
<td>$18.4</td>
<td>$90.00</td>
<td>$91.9K</td>
<td>834</td>
<td>50</td>
</tr>
<tr>
<td>NVO</td>
<td>看跌</td>
<td>掃描</td>
<td>看跌</td>
<td>12/20/24</td>
<td>$3.2</td>
<td>$3.0</td>
<td>$3.2</td>
<td>$103.00</td>
<td>$72.9K</td>
<td>2.1K</td>
<td>778</td>
</tr>
<tr>
<td>NVO</td>
<td>看跌</td>
<td>掃描</td>
<td>看跌</td>
<td>01/03/25</td>
<td>$3.25</td>
<td>$3.05</td>
<td>$3.24</td>
<td>$100.00</td>
<td>$56.6K</td>
<td>342</td>
<td>211</td>
</tr>
</tbody>
</table>
<h3>關於諾和諾德</h3>
<p>諾和諾德在全球品牌糖尿病治療市場中佔據大約三分之一的份額，是全球領先的糖尿病護理產品提供商。該公司總部位於丹麥，生產和銷售多種人用和現代胰島素、GLP-1 療法等注射糖尿病治療藥物、口服降糖藥和肥胖治療藥物。諾和諾德還擁有一個生物製藥部門（約佔收入的 10%），專注於治療血友病和其他疾病的蛋白質療法。</p>
<p>在研究了諾和諾德的期權交易模式後，我們的注意力現在直接轉向公司本身。這一轉變使我們能夠深入瞭解其當前的市場地位和表現。</p>
<h3>諾和諾德當前市場狀態</h3>
<ul>
<li>交易量為 3,835,436，NVO 的價格下跌了-2.67%，目前為 105.72 美元。</li>
<li>RSI 指標顯示該股票可能接近超買狀態。</li>
<li>預計在 47 天內發佈財報。</li>
</ul>
<p><strong>在短短 20 天內將 1000 美元變成 1270 美元？</strong></p>
<p>一位擁有 20 年經驗的期權交易員揭示了他的單行圖技術，顯示何時買入和賣出。複製他的交易，平均每 20 天獲得 27% 的利潤。<strong>點擊這裏獲取訪問權限</strong>。</p>
<p>交易期權涉及更大的風險，但也提供了更高的利潤潛力。精明的交易者通過持續教育、戰略性交易調整、利用各種指標以及關注市場動態來降低這些風險。通過 Benzinga Pro 跟蹤諾和諾德的最新期權交易，獲取實時警報。</p>

諾和諾德公司

<p>資金雄厚的投資者對諾和諾德公司（Novo Nordisk, NVO）表現出樂觀情緒，這從 Benzinga 跟蹤的顯著期權活動中可以看出。在這些顯著的期權中，52% 是看漲期權，而 35% 是看跌期權，總共有 9 個看跌期權和 8 個看漲期權。NVO 的目標價格似乎在 100.00 美元到 110.00 美元之間。目前的交易量為 3,835,436，NVO 的價格下跌了 2.67%，報 105.72 美元。預計將在 47 天后發佈財報</p>

<p>Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk NVO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVO usually suggests something big is about to happen.</p>
<div class="lb-trans"><p>資金雄厚的投資者對諾和諾德公司（Novo Nordisk NVO）採取了看漲的態度，這一點市場參與者不應忽視。我們在 Benzinga 跟蹤公共期權記錄時，今天揭示了這一重大舉動。這些投資者的身份仍然未知，但 NVO 的如此大規模動作通常暗示着一些重大事件即將發生。</p>
</div><p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for Novo Nordisk. This level of activity is out of the ordinary.</p>
<div class="lb-trans"><p>我們今天的觀察中得知這一信息，當 Benzinga 的期權掃描儀突出了諾和諾德的 17 個異常期權活動時。這種活動水平非常不尋常。</p>
</div><p>The general mood among these heavyweight investors is divided, with 52% leaning bullish and 35% bearish. Among these notable options, 9 are puts, totaling $352,686, and 8 are calls, amounting to $577,375.</p>
<div class="lb-trans"><p>這些重量級投資者的整體情緒分歧，52% 傾向於看漲，35% 看跌。在這些顯著的期權中，有 9 個是看跌期權，總計 352,686 美元，8 個是看漲期權，總計 577,375 美元。</p>
</div><h3>What's The Price Target?</h3>
<div class="lb-trans"><h3>價格目標是什麼？</h3>
</div><p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $75.0 to $155.0 for Novo Nordisk during the past quarter.</p>
<div class="lb-trans"><p>分析這些合約的成交量和未平倉合約，似乎大玩家在過去一個季度內關注諾和諾德的價格區間為 75.0 美元到 155.0 美元。</p>
</div><h3>Volume &amp; Open Interest Trends</h3>
<div class="lb-trans"><h3>成交量與未平倉合約趨勢</h3>
</div><p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<div class="lb-trans"><p>查看成交量和未平倉合約是對股票進行盡職調查的一個有益方式。</p>
</div><p>This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price.</p>
<div class="lb-trans"><p>這些數據可以幫助你跟蹤諾和諾德在特定行權價的期權流動性和興趣。</p>
</div><p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale activity within a strike price range from $75.0 to $155.0 in the last 30 days.</p>
<div class="lb-trans"><p>下面，我們可以觀察到諾和諾德在過去 30 天內所有鯨魚活動的看漲和看跌期權的成交量和未平倉合約的演變，行權價範圍為 75.0 美元到 155.0 美元。</p>
</div><h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<div class="lb-trans"><h3>諾和諾德過去 30 天的期權成交量和未平倉合約</h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2024/1734115610_0.png" alt="" original-src="https://www.benzinga.com/files/images/story/2024/1734115610_0.png"/></p>
<h3>Noteworthy Options Activity:</h3>
<div class="lb-trans"><h3>值得注意的期權活動：</h3>
</div><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.35</td>
<td>$3.15</td>
<td>$3.7</td>
<td>$109.00</td>
<td>$185.0K</td>
<td>1.0K</td>
<td>554</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.0</td>
<td>$4.8</td>
<td>$5.0</td>
<td>$110.00</td>
<td>$96.5K</td>
<td>3.9K</td>
<td>253</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$19.0</td>
<td>$17.9</td>
<td>$18.4</td>
<td>$90.00</td>
<td>$91.9K</td>
<td>834</td>
<td>50</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.2</td>
<td>$3.0</td>
<td>$3.2</td>
<td>$103.00</td>
<td>$72.9K</td>
<td>2.1K</td>
<td>778</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/03/25</td>
<td>$3.25</td>
<td>$3.05</td>
<td>$3.24</td>
<td>$100.00</td>
<td>$56.6K</td>
<td>342</td>
<td>211</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行權價</strong></th>
<th><strong>總交易價格</strong></th>
<th><strong>未平倉合約</strong></th>
<th><strong>成交量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>12/20/24</td>
<td>$3.35</td>
<td>$3.15</td>
<td>$3.7</td>
<td>$109.00</td>
<td>$185.0K</td>
<td>1.0K</td>
<td>554</td>
</tr>
<tr>
<td>NVO</td>
<td>看漲</td>
<td>掃描</td>
<td>看漲</td>
<td>01/17/25</td>
<td>$5.0</td>
<td>$4.8</td>
<td>$5.0</td>
<td>$110.00</td>
<td>$96.5K</td>
<td>3.9K</td>
<td>253</td>
</tr>
<tr>
<td>NVO</td>
<td>看漲</td>
<td>交易</td>
<td>中性</td>
<td>01/17/25</td>
<td>$19.0</td>
<td>$17.9</td>
<td>$18.4</td>
<td>$90.00</td>
<td>$91.9K</td>
<td>834</td>
<td>50</td>
</tr>
<tr>
<td>NVO</td>
<td>看跌</td>
<td>掃描</td>
<td>看跌</td>
<td>12/20/24</td>
<td>$3.2</td>
<td>$3.0</td>
<td>$3.2</td>
<td>$103.00</td>
<td>$72.9K</td>
<td>2.1K</td>
<td>778</td>
</tr>
<tr>
<td>NVO</td>
<td>看跌</td>
<td>掃描</td>
<td>看跌</td>
<td>01/03/25</td>
<td>$3.25</td>
<td>$3.05</td>
<td>$3.24</td>
<td>$100.00</td>
<td>$56.6K</td>
<td>342</td>
<td>211</td>
</tr>
</tbody>
</table>
</div><h3>About Novo Nordisk</h3>
<div class="lb-trans"><h3>關於諾和諾德</h3>
</div><p>With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.</p>
<div class="lb-trans"><p>諾和諾德在全球品牌糖尿病治療市場中佔據大約三分之一的份額，是全球領先的糖尿病護理產品提供商。該公司總部位於丹麥，生產和銷售多種人用和現代胰島素、GLP-1 療法等注射糖尿病治療藥物、口服降糖藥和肥胖治療藥物。諾和諾德還擁有一個生物製藥部門（約佔收入的 10%），專注於治療血友病和其他疾病的蛋白質療法。</p>
</div><p>Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<div class="lb-trans"><p>在研究了諾和諾德的期權交易模式後，我們的注意力現在直接轉向公司本身。這一轉變使我們能夠深入瞭解其當前的市場地位和表現。</p>
</div><h3>Novo Nordisk's Current Market Status</h3>
<div class="lb-trans"><h3>諾和諾德當前市場狀態</h3>
</div><ul>
<li>Trading volume stands at 3,835,436, with NVO's price down by -2.67%, positioned at $105.72.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 47 days.</li>
</ul>
<div class="lb-trans"><ul>
<li>交易量為 3,835,436，NVO 的價格下跌了-2.67%，目前為 105.72 美元。</li>
<li>RSI 指標顯示該股票可能接近超買狀態。</li>
<li>預計在 47 天內發佈財報。</li>
</ul>
</div><p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<div class="lb-trans"><p><strong>在短短 20 天內將 1000 美元變成 1270 美元？</strong></p>
</div><p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <strong>Click here for access</strong>.</p>
<div class="lb-trans"><p>一位擁有 20 年經驗的期權交易員揭示了他的單行圖技術，顯示何時買入和賣出。複製他的交易，平均每 20 天獲得 27% 的利潤。<strong>點擊這裏獲取訪問權限</strong>。</p>
</div><p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with Benzinga Pro for real-time alerts.</p>
<div class="lb-trans"><p>交易期權涉及更大的風險，但也提供了更高的利潤潛力。精明的交易者通過持續教育、戰略性交易調整、利用各種指標以及關注市場動態來降低這些風險。通過 Benzinga Pro 跟蹤諾和諾德的最新期權交易，獲取實時警報。</p>
</div>

市場巨頭及其最近對諾和諾德公司期權的投資